Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
DECABID vs PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
None Documented
None Documented
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Antiemetic